Video

Black patients show inferior survival despite similar cytogenetics and treatment response

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses

Empowering cancer care in Africa

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement

Latest in bladder cancer from the second half of 2025

IPSO guidelines on minimally invasive surgery in paediatric solid tumours

Principles and practice of prognostication

Avoiding burnout

Health and Peace